利那洛肽的研究进展及适应证的拓展  

Research progress and indications of linaclotide

作　　者：苏琪茗 伊丽娜 吴晓玮 张慧丽 杨勤[2] SU Qiming;YI Lina;WU Xiaowei

机构地区：[1]南京中医药大学,南京210029 [2]南京市中医院脾胃病科

出　　处：《中国中西医结合消化杂志》2022年第2期159-162,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

基　　金：江苏省研究生培养创新工程研究生科研与实践创新计划(No:SJCX21_0792)。

摘　　要：利那洛肽是一种新型的鸟苷酸环化酶C(GC-C)激动剂,属于肠道促分泌药,它可增加细胞内环磷酸鸟苷的水平,从而增加肠道分泌,提高患者痛阈,达到通便、止痛的效果[1]。目前利那洛肽在临床主要被批准用于治疗便秘型肠易激综合征(irritable bowel syndrome with constipation,IBS-C)和慢性特发性便秘(chronic idiopathic constipation,CIC),与传统通便药物相比。Linaclotide is a new type of guanylate cyclase C receptor agonist,an intestinal secretagogue.It can increase the level of cyclic guanosine phosphate in cells,thereby increasing intestinal secretion and patients’ pain threshold.Linaclotide is currently clinically approved for the treatment of constipation-type irritable bowel syndrome and chronic idiopathic constipation.Compared with traditional laxatives,linaclotide has a more substantial effect,stable drug effect,and systemic adverse events.In addition to the treatment of constipation-related diseases,linaclotide is mainly used for its unique mechanism of action.Intestinal preparation before colonoscopy,regulating the homeostasis of the intestinal barrier,inhibiting intestinal inflammation and preventing tumors have related effects.The clinical indications and research progress of linaclotide are reviewed in this paper.

关 键 词：利那洛肽 便秘型肠易激综合征 慢性特发性便秘 结肠炎 结肠肿瘤 

分 类 号：R256.3[医药卫生—中医内科学] R574.4[医药卫生—中医学]